search
Back to results

Comparative Hybrid Effects of Combining BoNT-A With Robot-assisted or Mirror Therapy for U/E Spasticity Stroke Patients

Primary Purpose

Stroke

Status
Completed
Phase
Phase 3
Locations
Taiwan
Study Type
Interventional
Intervention
Botulinum Toxin Type A
Robot-assisted therapy
Mirror therapy
Control intervention
Sponsored by
Chang Gung Memorial Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Stroke focused on measuring stroke rehabilitation, spasticity, Botulinum toxin type A injection, robot-assisted therapy, mirror therapy, randomized controlled trial

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Willing to provide written informed consent
  • Clinical and imagine diagnosis of a first or recurrent unilateral stroke ≥ 3 months
  • Upper limb spasticity (Modified Ashworth scale of ≥ 2)
  • Moderate to severe movement impairment of U/E (FMA score ranging from 18 to 56)
  • No serious cognitive impairment (i.e., Mini Mental State Exam score > 18)
  • Age ≥ 18 years

Exclusion Criteria:

  • Pregnant
  • Bilateral hemispheric or cerebellar lesions
  • Significant visual field deficits or hemineglect
  • Contraindication for BoNT-A injection

Sites / Locations

  • Department of Rehabilitation, Chang Gung Memorial Hospital-Kaohsiung Medical Center, Kaohsiung, Taiwan

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Active Comparator

Arm Label

Robot-assisted therapy (RT)

Mirror therapy (MT)

Control Intervention (CI)

Arm Description

After injection with Botulinum Toxin Type A, a schedule of robot-assisted therapy appointments will be established. Each intervention includes 45 minutes of robotic training and 30 minutes of training in functional activities.

After injection with Botulinum Toxin Type A, a schedule of mirror therapy appointments will be established.The MT group will receive a 45-minute MT per session followed by 30 minutes of task-oriented functional training.

After injection with Botulinum Toxin Type A, a schedule of control intervention appointments will be established.The CI group will receive 75-minute rehabilitation program, focusing on upper extremity training and including neurodevelopmental techniques, trunk-arm control, weight bearing by the affected arm, fine motor tasks practice, functional task practice, and practice on compensatory strategies for daily activities.

Outcomes

Primary Outcome Measures

Motor function assessed on Fugl-Meyer Assessment (FMA)
The outcome will be measured at 3 time points: 0 week, 8 weeks, and 5 months after recruitment.

Secondary Outcome Measures

Muscle power assessed on Medical Research Council Scale (MRC)
The outcome will be measured at 3 time points: 0 week, 8 weeks, and 5 months after recruitment.
Muscle tone assessed on Modified Ashworth Scale (MAS)
The outcome will be measured at 3 time points: 0 week, 8 weeks, and 5 months after recruitment.
The functional state assessed on Myometer Assessment
The outcome will be measured at 4 time points: 0 week, 1 week, 8 weeks, and 5 months after recruitment.
The amount of movement assessed on Actigraph Assessment
The outcome will be measured at 2 time points: 0 week, and 8 weeks after recruitment.
The quality of sleep assessed on Pittsburgh Sleep Quality Index (PSQI)
The outcome will be measured at 3 time points: 0 week, 8 weeks, and 5 months after recruitment.
Walking speed assessed on Ten Meter Walk Test (10MWT)
The outcome will be measured at 2 time points: 0 week, and 8 weeks after recruitment.
The upper extremity motor ability assessed on Wolf Motor Function Test (WMFT)
The outcome will be measured at 3 time points: 0 week, 8 weeks, and 5 months after recruitment.
The quality of movement and amount of use assessed on Motor Activity Log (MAL)
The outcome will be measured at 3 time points: 0 week, 8 weeks, and 5 months after recruitment.
The instrumental activities of daily living assessed on Nottingham Extended Activities of Daily Living Scale (NEADL)
The outcome will be measured at 3 time points: 0 week, 8 weeks, and 5 months after recruitment.
The participant's perception of the performance assessed on Canadian Occupational Performance Measure (COPM)
The outcome will be measured at 3 time points: 0 week, 1week, and 8 weeks after recruitment.
The participants' individual goals assessed on Goal attainment scale (GAS)
The outcome will be measured at 4 time points: 0 week, 1 week, 8 weeks, and 5 months after recruitment.
Revised Notttingham Sensory Assessment (RNSA)
The outcome will be measured at 3 time points: 0 week, 1week, and 8 weeks after recruitment.
Stroke Impact Scale (SIS)
The outcome will be measured at 4 time points: 0 week, 1 week, 8 weeks, and 5 months after recruitment.

Full Information

First Posted
April 7, 2016
Last Updated
July 17, 2018
Sponsor
Chang Gung Memorial Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT02749591
Brief Title
Comparative Hybrid Effects of Combining BoNT-A With Robot-assisted or Mirror Therapy for U/E Spasticity Stroke Patients
Official Title
Comparative Hybrid Effects of Combining Botulinum Toxin Type A With Robot-assisted Training v.s. With Mirror Therapy for Stroke Patients With Upper Extremity Spasticity: A Randomized Controlled Study
Study Type
Interventional

2. Study Status

Record Verification Date
May 2017
Overall Recruitment Status
Completed
Study Start Date
May 2, 2016 (Actual)
Primary Completion Date
November 2017 (Actual)
Study Completion Date
November 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Chang Gung Memorial Hospital

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The aim of this study will be to determine and compare the immediate and longer-term effects of combination of BoNT-A injection and mirror therapy vs combination of BoNT-A injection and robot-assisted therapy.
Detailed Description
The purpose of this project is to examine and compare the immediate and long-term effects of combined Botulinum toxin type A injection with mirror therapy (MT) and with bilateral robot-assisted (RT) in patients with spastic hemiplegic stroke. Spasticity, a common impairment after stroke, has a profound impact on activity and participation for patients. BoNT-A injection combined with rehabilitation training is recommended to enhance functional recovery for stroke patients with spasticity. Although the positive combination effects of BoNT-A with stretch, RT, and constraint-induced movement therapy were reported, the quality of the evidence was weak due to methodology limitations. In addition, patients with spasticity usually have lower motor function and worse sensory deficits than patients without spasticity. Designing the post BoNT-A injection rehabilitation program should consider the above issues. RT and MT are two interventions providing sensorimotor input for patient with low level of motor function. It is unknown whether combining BoNT-A injection with RT or with MT have positive effects and engenders differential effects on motor and related functional performance. At least 60 participants with chronic spastic hemiplegic stroke will be recruited and randomly assigned to one of 3 groups: BoNT-A injection with RT, BoNT-A injection with MT, and BoNT-A injection with control intervention (CI). All the post-injection interventions will be implemented 60 minutes/day, 3 days/week, for 8 weeks. The RT group will receive 30-minute RT, followed by 30-minute functional training. The MT group will receive 30-minute MT, followed by 30-minute functional training. The CI group will receive 60-minute rehabilitation program, such as bilateral arm training and functional task practice. Body function and structures outcome measures include Fugl-Meyer Assessment, Modified Ashworth Scale, Medical Research Council scale, myometer (Myoton-3), actigraph, and Pittsburgh Sleep Quality Index. Activity and participation measures include Wolf Motor Function Test, Ten meter walk test, Motor Activity Log, Nottingham Extended Activities of Daily Living Scale, and Canadian Occupational Performance Measure. In addition, to directly reflect a patient's unique needs and goals, Goal Attainment Scaling will be assessed. Evaluators will be blind to group allocation. The outcome will be measured at pre-treatment, post-treatment, and 3-month follow-up. This comparative efficacy study will be the first to examine and compare the immediate and long-term combination effects of BoNT injection with RT, MT, or CI. The follow-up assessments will provide the long-term effects of different treatments on health-related outcomes, which are crucial for community reentry. In addition, the results of objective assessments and patient-reported outcomes may lead to individualized upper limb training following BoNT-A injection for patients with spastic hemiplegic stroke.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Stroke
Keywords
stroke rehabilitation, spasticity, Botulinum toxin type A injection, robot-assisted therapy, mirror therapy, randomized controlled trial

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
37 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Robot-assisted therapy (RT)
Arm Type
Experimental
Arm Description
After injection with Botulinum Toxin Type A, a schedule of robot-assisted therapy appointments will be established. Each intervention includes 45 minutes of robotic training and 30 minutes of training in functional activities.
Arm Title
Mirror therapy (MT)
Arm Type
Experimental
Arm Description
After injection with Botulinum Toxin Type A, a schedule of mirror therapy appointments will be established.The MT group will receive a 45-minute MT per session followed by 30 minutes of task-oriented functional training.
Arm Title
Control Intervention (CI)
Arm Type
Active Comparator
Arm Description
After injection with Botulinum Toxin Type A, a schedule of control intervention appointments will be established.The CI group will receive 75-minute rehabilitation program, focusing on upper extremity training and including neurodevelopmental techniques, trunk-arm control, weight bearing by the affected arm, fine motor tasks practice, functional task practice, and practice on compensatory strategies for daily activities.
Intervention Type
Drug
Intervention Name(s)
Botulinum Toxin Type A
Other Intervention Name(s)
Botulinum Toxin
Intervention Description
To inject Botulinum toxin type A on the spasticity upper extremity for stroke patients.Doses and muscles selected for BoNT-A injection are individualized on the basis of a number of factors, including the spasticity patterns, severity of spasticity, and treatment goals
Intervention Type
Other
Intervention Name(s)
Robot-assisted therapy
Intervention Description
After injecting Botulinum toxin type A on the spasticity upper extremity, the RT group will receive a 45 minutes of robotic training and 30 minutes of training in functional training.
Intervention Type
Other
Intervention Name(s)
Mirror therapy
Intervention Description
After injecting Botulinum toxin type A on the spasticity upper extremity, the MT group will receive a 45-minute MT per session followed by 30 minutes of task-oriented functional training.
Intervention Type
Other
Intervention Name(s)
Control intervention
Intervention Description
After injecting Botulinum toxin type A on the spasticity upper extremity, the CI group will receive 75-minute rehabilitation program, focusing on upper extremity training and including neurodevelopmental techniques, trunk-arm control, weight bearing by the affected arm, fine motor tasks practice, functional task practice, and practice on compensatory strategies for daily activities.
Primary Outcome Measure Information:
Title
Motor function assessed on Fugl-Meyer Assessment (FMA)
Description
The outcome will be measured at 3 time points: 0 week, 8 weeks, and 5 months after recruitment.
Time Frame
Change from baseline at 5 months
Secondary Outcome Measure Information:
Title
Muscle power assessed on Medical Research Council Scale (MRC)
Description
The outcome will be measured at 3 time points: 0 week, 8 weeks, and 5 months after recruitment.
Time Frame
Change from baseline at 5 months
Title
Muscle tone assessed on Modified Ashworth Scale (MAS)
Description
The outcome will be measured at 3 time points: 0 week, 8 weeks, and 5 months after recruitment.
Time Frame
Change from baseline at 5 months
Title
The functional state assessed on Myometer Assessment
Description
The outcome will be measured at 4 time points: 0 week, 1 week, 8 weeks, and 5 months after recruitment.
Time Frame
Change from baseline at 5 months
Title
The amount of movement assessed on Actigraph Assessment
Description
The outcome will be measured at 2 time points: 0 week, and 8 weeks after recruitment.
Time Frame
Change from baseline at 2 months
Title
The quality of sleep assessed on Pittsburgh Sleep Quality Index (PSQI)
Description
The outcome will be measured at 3 time points: 0 week, 8 weeks, and 5 months after recruitment.
Time Frame
Change from baseline at 5 months
Title
Walking speed assessed on Ten Meter Walk Test (10MWT)
Description
The outcome will be measured at 2 time points: 0 week, and 8 weeks after recruitment.
Time Frame
Change from baseline at 2 months
Title
The upper extremity motor ability assessed on Wolf Motor Function Test (WMFT)
Description
The outcome will be measured at 3 time points: 0 week, 8 weeks, and 5 months after recruitment.
Time Frame
Change from baseline at 5 months
Title
The quality of movement and amount of use assessed on Motor Activity Log (MAL)
Description
The outcome will be measured at 3 time points: 0 week, 8 weeks, and 5 months after recruitment.
Time Frame
Change from baseline at 5 months
Title
The instrumental activities of daily living assessed on Nottingham Extended Activities of Daily Living Scale (NEADL)
Description
The outcome will be measured at 3 time points: 0 week, 8 weeks, and 5 months after recruitment.
Time Frame
Change from baseline at 5 months
Title
The participant's perception of the performance assessed on Canadian Occupational Performance Measure (COPM)
Description
The outcome will be measured at 3 time points: 0 week, 1week, and 8 weeks after recruitment.
Time Frame
Change from baseline at 2 months
Title
The participants' individual goals assessed on Goal attainment scale (GAS)
Description
The outcome will be measured at 4 time points: 0 week, 1 week, 8 weeks, and 5 months after recruitment.
Time Frame
Change from baseline at 5 months
Title
Revised Notttingham Sensory Assessment (RNSA)
Description
The outcome will be measured at 3 time points: 0 week, 1week, and 8 weeks after recruitment.
Time Frame
Change from baseline at 2 months
Title
Stroke Impact Scale (SIS)
Description
The outcome will be measured at 4 time points: 0 week, 1 week, 8 weeks, and 5 months after recruitment.
Time Frame
Change from baseline at 5 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Willing to provide written informed consent Clinical and imagine diagnosis of a first or recurrent unilateral stroke ≥ 3 months Upper limb spasticity (Modified Ashworth scale of ≥ 2) Moderate to severe movement impairment of U/E (FMA score ranging from 18 to 56) No serious cognitive impairment (i.e., Mini Mental State Exam score > 18) Age ≥ 18 years Exclusion Criteria: Pregnant Bilateral hemispheric or cerebellar lesions Significant visual field deficits or hemineglect Contraindication for BoNT-A injection
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jen-Wen Hung
Organizational Affiliation
Chang Gung Memorial Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Department of Rehabilitation, Chang Gung Memorial Hospital-Kaohsiung Medical Center, Kaohsiung, Taiwan
City
Kaohsiung
ZIP/Postal Code
833
Country
Taiwan

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
16777777
Citation
Ada L, O'Dwyer N, O'Neill E. Relation between spasticity, weakness and contracture of the elbow flexors and upper limb activity after stroke: an observational study. Disabil Rehabil. 2006 Jul 15-30;28(13-14):891-7. doi: 10.1080/09638280500535165.
Results Reference
result
PubMed Identifier
25592185
Citation
Amano S, Takebayashi T, Hanada K, Umeji A, Marumoto K, Furukawa K, Domen K. Constraint-Induced Movement Therapy After Injection of Botulinum Toxin Type A for a Patient With Chronic Stroke: One-Year Follow-up Case Report. Phys Ther. 2015 Jul;95(7):1039-45. doi: 10.2522/ptj.20140329. Epub 2015 Jan 15.
Results Reference
result
PubMed Identifier
10896696
Citation
Bhakta BB, Cozens JA, Chamberlain MA, Bamford JM. Impact of botulinum toxin type A on disability and carer burden due to arm spasticity after stroke: a randomised double blind placebo controlled trial. J Neurol Neurosurg Psychiatry. 2000 Aug;69(2):217-21. doi: 10.1136/jnnp.69.2.217. Erratum In: J Neurol Neurosurg Psychiatry 2001 Jun;70(6):821.
Results Reference
result
PubMed Identifier
3809245
Citation
Bohannon RW, Smith MB. Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther. 1987 Feb;67(2):206-7. doi: 10.1093/ptj/67.2.206.
Results Reference
result

Learn more about this trial

Comparative Hybrid Effects of Combining BoNT-A With Robot-assisted or Mirror Therapy for U/E Spasticity Stroke Patients

We'll reach out to this number within 24 hrs